Cancer Research Breakthroughs at the Abramson Cancer Center


Discovery of the Philadelphia Chromosome — the first evidence that abnormal chromosomes can cause cancer.

Development of antibody approaches to fighting cancer, leading the way in targeted cancer treatment, including the breast cancer drug Herceptin®.

Transoral robotic surgery (TORS), a breakthrough minimally invasive procedure approved by the Food and Drug Administration, can remove tumors in head and neck patients and actually reduce healing time.

Discovery of a new diagnostic marker for mutations found in over 70 percent of gliomas and 25 percent of leukemia.

Evidence that patients whose immune systems responded to ovarian cancer by producing a specific kind of immune cell, called a tumor infiltrating T-cell, have significantly better outcomes than those who did not have the immune response.

The first evidence that the type 2 diabetes drug metformin can inhibit the growth of tumors.

Proof-of-concept trials that found the BRAF gene mutation can be a therapeutic target for melanoma.

First known oncogenic mutation in the germline identified in families with inherited form of neuroblastoma.

Demonstrated the potential use of MRI to enhance breast cancer screening in high risk individuals.

Provided evidence of sustained remissions of up to a year among a small group of chronic lymphocytic leukemia patients treated with genetically engineered versions of their own T-cells.

Engineered a second generation of T-cells that can eradicate deadly ovarian cancer.